Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Week Study Conducted at Multiple Centers, Blinded to Both the Patient and Doctor, Evaluating for Safety and Effectiveness Two Dosages of an Investigational Agent (GM-611) Versus a Placebo, That Are Randomly Assigned to Patients With Diabetic Gastroparesis

NCT00050882 is registered in ClinicalTrials.gov with Chugai Pharma USA as lead sponsor.

NCT NCT00050882
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00050882 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Week Study Conducted at Multiple Centers, Blinded to Both the Patient and Doctor, Evaluating for Safety and Effectiveness Two Dosages of an Investigational Agent (GM-611) Versus a Placebo, That Are Randomly Assigned to Patients With Diabetic Gastroparesis
Lead sponsor
Chugai Pharma USA
Phase
Phase 2
Overall status
Completed
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

gastroparesis